<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Transforming Drug Discovery with 3D Adult Stem Cell Organoids and High Content Imaging

3D adult stem cell (ASC)-derived tumor organoids can enhance the translatability of drug discovery data, especially in combination with high content imaging (HCI). In this blog post, we explore how the pairing of these two technologies allows researchers to develop highly comprehensive and predictive data that can enable better decisions earlier in drug discovery, while improving the translatability of the most promising lead compounds.

Current Challenges in Oncology Drug Discovery

Inter- and intra-tumor heterogeneity represents a persistent challenge in the treatment of cancer and is recognized as a major hurdle in the development of novel, safe and effective anti-cancer drugs. Despite the massive investment put forth to develop these drugs, which can take many years and billions of dollars, success has been relatively limited.

For instance, one analysis found that oncology clinical trials have a 97% rate of failure; albeit those that employ a biomarker strategy for patient-selection have higher overall success probabilities. The root cause of this statistic is due, in part, to the fact that most high throughput drug screens are conducted on 2D cell lines that are easy to establish and manipulate and can provide rapid results for early-stage decisions.

However, their physiological relevance is not ideal. For example, an analysis showed that immortalized cell lines grown in vitro and engrafted in vivo bear minimal resemblance to the tissue or tumor of origin. In addition, cell lines that have been adapted to grow outside their 3D tumor microenvironment (TME) are exposed to stressors and genetic changes that do not accurately recapitulate what occurs in patients. Thus, there is a need for more patient-relevant in vitro models that can help reduce the high rate of attrition of drugs in oncology development.

3D In Vitro Organoids for Drug Screening

As described in more depth in previous posts (such as here and here), tumor organoids are superior in vitro 3D cultures developed using exclusive Hubrecht Organoid Technology (HUB) protocols. Building upon important discoveries in ASC biology, HUB organoids can be generated from purified single ASCs or tissue fragments that harbor resident cells with stem activity when grown under 3D conditions (e.g., intestinal crypts). Importantly, ASC-derived organoids reflect the 3D complexity found in vivo. Since the first report on the use of HUB technology to generate ‘mini-gut’ organoids, protocols have been adapted and refined to a wide variety of tissues and permit long-term expansion of organoids with maintenance through serial passaging as well as cryopreservation for future use.

Unlike other 3D in vitro systems such as spheroids, which rely on spontaneous cell aggregation, the formation of HUB organoids is driven by the unique properties of stem cells which results in many shared features with in vivo tissues such as morphology, genetic make-up and physiological functions, making them highly patient-relevant 3D in vitro tumor models for drug screening.

Tumor organoids are also highly amenable to genetic manipulation. Gene editing technologies such as RNA interference or CRISPR/Cas9 can be used to generate custom models with specific genetic perturbations that are useful in the identification and validation of biological targets and mechanistic biomarkers.

Maximizing the efficiency of 3D in vitro organoids in drug screening can be achieved by pairing it with powerful HCI technology that can penetrate the 3D structure and visualize the dynamic interplay of cells and their response to drug candidates.

The Value of Pairing 3D In Vitro Organoids with HCI

As described in a previous post, HCI generally describes automated image-based high-throughput technology and HCI and analysis (HCA) indicates multiparameter algorithms applied to HCI data. HCI and HCA platforms allow researchers to visualize and quantify the interactions of drugs with cells. Pairing patient-relevant 3D in vitro tumor organoids with innovative HCI and HCA can generate extremely detailed cellular physiology profiles of complex cellular systems, including multicellular structures from organoids and co-cultures, such as co-culturing tumor organoids with immune cells for immunotherapy efficacy studies.

HCI significantly expands the amount of information obtained from cellular assays as compared to fixed endpoint assays such as Cell-Titer Glow (CTG) or nuclei count. By combining 3D organoids with HCI early in the target/drug discovery process, the risk of downstream failure can be mitigated since only the most-promising candidates, tested on highly patient-relevant 3D models, proceed through the drug discovery pipeline. Organoid and HCI platforms are being used together for drug combination studies to inform the potential course of action for difficult-to-treat tumors that are resistant to primary treatment.

The Value of Ready-to-Use Organoid Biobanks

Commercially available tumor organoid libraries, such as OrganoidBase™, allow researchers to access a cloud-based searchable database of patient-derived organoid (PDO) tumor models, with matched healthy organoids, for a range of cancer types, including breast, colorectal, and pancreatic, annotated with related histopathology, IC50, genomic, and transcriptomic analysis data. Biobanks capture the mutational diversity of tumors encountered by oncologists and provide a robust model to investigate disease progression, identify potential therapeutics, and study variation in drug responses produced in different patients with the same pathologies.

Further, tumor organoid biobanks are excellent platforms for screening multiple lead compounds where high-throughput screening (HTS) instruments dispense organoids into 384-well plates and introduce compounds to each well. While efficacy of lead compounds on biological targets can be monitored using traditional in vitro assays (e.g., cell viability and proliferation assays), HCI is increasingly being used to develop comprehensive data on changes in cellular response to drug candidates in high-throughput fashion.

Conclusion

Transforming drug discovery with 3D adult stem cell organoids and high content imaging aids in assessing drug toxicity, visualizing, and quantifying optimal drug concentrations, and monitoring off-target effects. These technologies allow researchers to identify biological targets, select leading drug candidates, and test drug responses in patient-relevant samples so that better decisions can be made earlier in the drug discovery process, and thus, increase the likelihood of developing a successful therapeutic.

Crown Bioscience provides researchers with tumor-specific 3D organoids for several indications through the OrganoidBase online database. Download our eBook to learn more about OrganoidBase.


Related Posts